Tag: clinical trials

Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders

Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders

| February 1, 2016 | 2 Comments

by the CNS SUMMIT DATA QUALITY MONITORING WORKGROUP CORE MEMBERS—David Daniel, MD; Amir Kalali, MD; Mark West; David Walling, PhD; Dana Hilt, MD; Nina Engelhardt, PhD; Larry Alphs, MD, PhD; Antony Loebel, MD; Kim Vanover, PhD; Sarah Atkinson, MD; Mark Opler, PhD, MPH; Gary Sachs, MD; Kari Nations, PhD; and Chris Brady, PsyD Dr. Daniel […]

Continue Reading

The Neuroscience Report—Vol. 24 (October 12, 2015): Treatment Paradigm Shifts in CNS

The Neuroscience Report—Vol. 24 (October 12, 2015): Treatment Paradigm Shifts in CNS

| October 12, 2015 | 0 Comments

The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to 5 journal articles, 5 news articles, and 5 wildcard picks. Brought to you by Innovations in Clinical Neuroscience—your source for peer-reviewed, evidence-based information. This Week’s Topic: Treatment […]

Continue Reading

Editor’s Message and January-February 2015 Issue Highlights

Editor’s Message and January-February 2015 Issue Highlights

| February 25, 2015 | 0 Comments

Dear Colleagues: Welcome to the January-February 2015 issue of Innovations in Clinical Neuroscience and to the beginning of our 12th year of publication. Over the years, we have sought to not only provide you with information on the latest, evidence-based treatment techniques for your patients, but also with information on how these new treatments are […]

Continue Reading

How Can Registries Contribute to the Development and Evaluation of CNS Therapeutics?

How Can Registries Contribute to the Development and Evaluation of CNS Therapeutics?

| June 1, 2013 | 0 Comments

by Joanne B. Severe, MS, and Annette Stemhagen, DrPH, FISPE Ms. Severe is a research consultant in Rockville, Maryland, and Dr. Stemhagen is with United Biosource Corp. in Bethesda, Maryland. Innov Clin Neurosci. 2013;10(5–6 Suppl A):29S–31S

Continue Reading

Estimating the Size of Treatment Effects: Moving Beyond P Values

Estimating the Size of Treatment Effects: Moving Beyond P Values

| October 31, 2009 | 0 Comments

by James J. McGough, MD, and Stephen V. Faraone, PhD Dr. McGough is Professor of Clinical Psychiatry at the Semel Institute for Neuroscience and Human Behavior and David Geffen School of Medicine at the University of California, Los Angeles. Dr. Faraone is Professor of Psychiatry and Behavioral Sciences at the State University of New York […]

Continue Reading